MANGOCEUTICALS INC.NEW Aktie

Mangoceuticals has entered into a definitive combination agreement with Nuclea Energy under which a newly formed subsidiary will merge with Nuclea and the result will be an indirect wholly owned subsidiary of Mangoceuticals. Nuclea is developing the lead‑cooled, graphite‑moderated micro‑modular reactor Morpheus, with a power scale of roughly 3.5 MWe to 50 MWe, and envisages applications including data centers, defense facilities and remote communities. Nuclea shareholders will receive exchangeable subsidiary shares on a one‑for‑one basis, with their rights limited prior to closing to 19.99% of Mangoceuticals’ outstanding common shares; closing is subject to shareholder approval and NASDAQ/SEC approvals. » Plus sur de.investing.com

Mangoceuticals has filed a lawsuit against Clarity Ventures in a Texas court seeking more than $73 million plus interest, costs and attorneys’ fees. The company alleges Clarity failed to deliver a fully functional, HIPAA-compliant ERP and e-commerce platform; Clarity denies the claims and has filed a counterclaim over allegedly unpaid invoices. Mangoceuticals says it made all payments and has since developed its own in‑house telemedicine and e-commerce platform; the stock recently suffered a sharp decline and the company reported falling revenues (down 38% to $0.47 million) with a gross margin of 60.61%. » Plus sur de.investing.com

Mangoceuticals announced a treasury strategy to invest up to $100 million into the Solana blockchain through its newly formed subsidiary Mango DAT. The Cube Group has been appointed as asset manager; the target is staking yields of 7–8% annually with active management potential of 8–20%. To finance the plan the company intends to use its shelf registration; a successful sale of the securities is not guaranteed. Additionally, Mangoceuticals recently raised $2.5 million through a registered direct placement and is continuing to expand its telemedicine offerings after denying partnership claims with Novo Nordisk and Eli Lilly. » Plus sur de.investing.com